Patricia LoRusso, DO, discusses the importance clinical trial enrollment for patients with MDM2-amplified dedifferentiated liposarcoma.
Patricia LoRusso, DO
Advertisement
Articles by Patricia LoRusso, DO
Patricia LoRusso, DO, discusses the efficacy observed of BI 907828 in solid tumors in a phase 1 trial.
Patricia LoRusso, DO, professor of Medicine (Medical Oncology), associate director, Innovative Medicine, Yale Cancer Center, discusses the role of PARP inhibitors in triple negative breast cancer.
Advertisement
Latest Updated Articles
Dr. LoRusso on the Efficacy of BI 907828 in Solid TumorsPublished: May 12th 2022 | Updated:
Dr. LoRusso on PARP Inhibitors in Triple-Negative Breast CancerPublished: September 30th 2016 | Updated:
Dr. LoRusso on the Importance of Clinical Trials in MDM2-Amplified Dedifferentiated LiposarcomaPublished: May 19th 2022 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5